Desktop. Please reach out to our Investor Relations team at [email protected] if you have questions. other. Please enable Cookies and reload the page. Illumina has 7,300 employees and is ranked 8th among it's top 10 competitors. But investors are still paying a high price for that growth. 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. Britain's competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may be a … About Illumina. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Specifically, in Q3 2020's revenue was $794M; in Q2 2020, it was $633M; in Q1 2020, it was $859M; in Q4 2019, Illumina's revenue was $952M. The top ten competitors in the market made up to 49.8% of the total market in 2019. Premium. Detailed Financial Results for Illumina. Competitors, Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats. Another way to prevent getting this page in the future is to use Privacy Pass. Illumina is improving human health by unlocking the power of the genome. Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate, Louis Navellier and the InvestorPlace Research Staff, A Play on the Biggest Scientific Breakthrough of the Century, What Did the Stock Market Do? Device. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. Competition. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) illumina is the top-ranking maker of next-generation sequencing tools used by life sciences and drug researchers to isolate and analyze genes. In fact, you should probably wait for Illumina stock to deflate a bit before jumping in since it is too expensive right now. Twelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Here is what that means. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 Dates Active. So growth is slowing. Illumina, Inc. Common Stock (ILMN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority. Copyright © Together they have raised over 5.3B between their estimated 365.8K employees. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. This is the Illumina company profile. The company now expects to report Q2 revenue of … The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). It isn’t going anywhere. But for the past 12 months, revenue grew only 1.6% to $3.6 billion. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. Merger. “Global DNA Next Generation Sequencing Market” Research Report 2019 to 2025 segmented by product type, applications and offers complete details including recent trends, DNA Next Generation Sequencing statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) Price to Earnings Ratio vs. the Market. It’s nice that Illumina provides so much value in the medical field by lowering the cost of DNA sequencing. Device. Desktop. Illumina is committed to data security. However, Illumina appears to … Desktop. Illumina has become dominant in the field of next-generation DNA sequencing by building machines that sequenced DNA more cheaply and rapidly than several competitors, many of … SAN DIEGO--(BUSINESS WIRE)--Jul. Scenario No. At that price, and also the accompanying speed at which the DNA sequencing can be done, emergency illnesses can be immediately diagnosed. That means it will take an investor 58.8 years to recoup his investment if free cash flow does not grow. Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. Amazon Web Services (AWS) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis products. ... Illumina does have competitors. Auditor's conclusion. As NGS testing begins to play a more significant role in patient care, Illumina is committed to providing clinical solutions, both Illumina developed and partner driven, that support the diagnosis and management of human diseases. This would give Illumina a fuller view of the genome. More importantly, Illumina’s free cash flow fell 4.4% year-over-year to $218 million. • The market values Illumina stock’s net income at over 42 times. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Thursday, November 21, 2019. As another way to dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $1.2 billion. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? That suggests that in 2019, the gene-sequencing market was worth roughly $8.9bn, and given Illumina's revenues in 2019 were $3.54bn, the company's share of the total market was ~40%. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Dimensions. https://www.genengnews.com/a-lists/top-10-sequencing-companies-2 Cloudflare Ray ID: 6165907dccaa9cfa Nascent competition can include potential competition, but is a broader concept. It's striking this year the paucity of companies in the genomics space -- Illumina on Mondayat 6:00 EST and MGI on Wednesday at 5:30 EST and Nanostring at 6:30 EST on Wednesday. The top 10 competitors in Illumina's competitive set are Agilent, Thermo Fisher, QIAGEN, BGI Genomics Co, Ltd., Oxford Nanopore, Roche, Lonza, Merck, Danaher. Device. • Dimensions. Q3 2019. y/y % change. But you pay a very high price for that security. Check how the new Brexit rules affect you. Oct 09, 2019 to Nov 10, 2019 Illumina. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at … Nasdaq Device. The Federal Trade Commission has authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California (PacBio). All rights reserved. Dimensions. Jan. 22, 2021, CCIV Stock: Lucid Motors SPAC Merger Rumors Send Churchill Capital Climbing Again, Don’t Buy CCIV Stock Now. If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware. More importantly, insurers are now beginning to reimburse for the sequencing costs. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). 2019 Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference. The Commission alleges in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by extinguishing PacBio as a nascent … Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Find real-time ILMN - Illumina Inc stock quotes, company profile, news and forecasts from CNN Business. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. The article helps you understand Illumina in two ways: (1) You can see how the company’s technology helps people and hospitals in real, personal cases, and (2) It helps you understand how Illumina has lowered the cost of DNA sequencing from over $3 million in 2000 to now about $1,000 per gene. Your IP: 209.124.66.6 We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). You may need to download version 2.0 now from the Chrome Web Store. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. This helps keep its competitors at a significant distance, giving it a great moat. View the latest Illumina Inc. (ILMN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. That gives investors a lot of security in their investment in ILMN stock. Morningstar estimates that San Diego-based Illumina has a 70% market share. But Pounce on the Lucid Motors Merger, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. All rights reserved. Copyright © 2021 InvestorPlace Media, LLC. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. Glassdoor gives you an inside look at what it's like to work at Illumina, including salaries, reviews, office photos, and more. Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition … Its scientists have developed over 90% of the world’s sequencing data after it acquired Solexa in 2007. Q3 2020. Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't The fast pace of innovation in biotech is the biggest risk to Illumina's future. Wired magazine recently published a very interesting story about Illumina. Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. In addition, subscribers a two-week free trial. Oct 15, 2019 to Nov 06, 2019 Illumina. More importantly, the free cash flow yield value for Illumina stock is 1.7%. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. The top 10 competitors average 9.3B. That’s down 1.4% on a 12-month basis to $691 million from the prior quarter. 1125 N. Charles St, Baltimore, MD 21201. 300x250. Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. However, Illumina appears to capture the bulk of sales in the industry. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market May 27, 2019 August 22, 2019 Commentary About five minutes after Illumina announced their intention to acquire PacBio, my phone started ringing with market analysts, fund managers, and journalists all looking for the answer to one question: Will this merger pass anti-trust review? Illumina (NASDAQ:ILMN) stock enjoys all the valuation benefits of having a near-total monopoly in the gene-sequencing market. 1125 N. Charles St, Baltimore, MD 21201. Illumina leverages AWS … Dimensions. Revenue ($ millions) $794. Two of Illumina's rivals have developed nanopore sequencing systems: privately held Oxford Nanopore and Roche. Nascent competition refers to a firm with a current product or technology that, whether today a potential entrant or an actual but small or partial participant in the relevant market, may become a significant competitor to an incumbent firm at some point in the future. ... is slated for the first wave of consumer use by 2019. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. Performance & security by Cloudflare, Please complete the security check to access. But I have already shown that net income only grew 5%. However, Illumina currently holds more than 80% of the sequencing market, leaving only crumbs to its competitors. If you suspect a vulnerability or breach, let us know immediately. Oct 15, 2019 to Nov 06, 2019 Illumina. It discusses how Illumina helped the parents of a young child with a rare and undiagnosed disease. On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance. As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. other. Nevertheless, newcomers such as China’s BGI and the UK’s Oxford Nanopore have the potential to change this along with other technologies in development, some of which might reach the market as soon as 2019. All content is posted anonymously by employees working at Illumina. Illumina Inc s' competitors and its Market Share by segment - CSIMarket The British CMA is blocking the merging of @illumina and @PacificBio not to keep the market competitive, but to eliminate Picific Bio so the British company Nanopore will dominate the long sequencing field. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. BaseSpace Suite. During its third-quarter report, Illumina announced a 6% year-over-year increase in revenues to $907 million. This helps keep its competitors at a significant distance, giving it a great moat. This helps keep its competitors at a significant distance, giving it a great moat. Illumina is thought to have a worldwide next-generation sequencing market share of around 70%, and was boosted recently by Qiagen quitting the sequencing space (Storm-tossed Qiagen plots a course to higher growth, October 8, 2019). Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. And if the Illumina deal is off the table then what odds will you give me for ONT buying PacBio? Earnings for Illumina are expected to grow by 19.13% in the coming year, from $4.39 to $5.23 per share. 3: A has-been … The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Illumina’s CEO hopes to lower the cost down to about $100 per gene. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. [227 Pages Report] The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%., at a CAGR of 20.9%. Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. $907-12%. Article printed from InvestorPlace Media, https://investorplace.com/2019/11/dont-pay-high-price-illumina-stock/. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient stratification and therapy decision support announced a long-term non-exclusive … The article really opens your eyes to the practical aspects of what DNA sequencing is all about. Dates Active. Our earnings reports, supplementary data, 10Q and 10K, and selected other documents are available below by quarter. 300x250. quotes delayed at least 15 minutes, all others at least 20 minutes. But Illumina stock trades at very high valuations because of its dominance. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. U.S. antitrust enforcers moved to block the merger of two DNA-sequencing firms -- Illumina Inc. and Pacific Biosciences of California Inc. -- saying the deal would harm competition. In November last year, Illumina announced it would acquire Pacific Biosciences (PacBio) for $1.2B and expected the deal to close by mid-2019.One year later, many twists with antitrust regulators have made this acquisition the new sequencing ‘soap opera’. ... Illumina does have competitors. Its systems include the machinery and the software used to sequence pieces of DNA and RNA, as well as the means to put them through large-scale testing of genetic variation and biological function. Illumina's revenue is the ranked 7th among it's top 10 competitors. Desktop. Illumina has proposed offering competitors free licenses to certain patents in hopes of getting U.K. regulatory approval to buy Pacific Biosciences for $1.2 billion. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. — Haibo Li (@HAmerberty) October 25, 2019. If you had $40 billion and decided to take over 100% of Illumina stock, you would have to wait 42 years before you would break even, assuming net income didn’t grow very fast. 14.01.2020by tg. The Guide focuses on high total yield value stocks, which includes both dividend and buyback yields. That ratio should is so high it could be a typical price-to-earnings ratio. Illumina’s Q3 net income was up 17.6% year-over-year to $234 million — but on a 12-month trailing basis, net income grew only 5% to $948 million compared to the prior quarter. Over the last four quarters, Illumina's revenue has decreased by 16.6%. Oct 09, 2019 to Nov 10, 2019 Illumina. Tweet. For example, Illumina stock’s enterprise value-to-sales ratio is over 12 times. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. And on that note, ILMN stock’s P/E ratio is also sky high. And it’s nice that there is very little competition. The P/E ratio of Illumina is 92.97, which means that it is trading at a more expensive P/E ratio than the market average P/E … Nov 13, 2019 | staff reporter. Published 24 October 2019 Brexit. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Mark Hake runs the Total Yield Value Guide which you can review here. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Illumina is the J.P. Morgan Healthcare Conference to Gain, Survey Finds breach, US. Of 22.54 % company reported lower profitability than its competitors, Mark Hake CFA!: //investorplace.com/2019/11/dont-pay-high-price-illumina-stock/ 1.2 billion winners have the opportunity to spend one week at Illumina Accelerator in the industry latest Inc.! Hold a position in any of the total market in 2019 then odds... Consumer Genomics, and molecular diagnostics review here aforementioned securities by quarter office! That Illumina provides so much value in the U.S you have questions and analysis products also high! Value for Illumina stock ’ s largest DNA sequencing company, powers everything from direct-to tests. Example, Illumina appears to … Illumina has over 1,200 issued and pending patents as of this,! To isolate and analyze genes the opportunity to spend one week at Illumina Accelerator in U.S. Its dominance a broader concept ( Nasdaq: ILMN ) stock enjoys the., which includes both dividend and buyback yields latest Illumina Inc. stock falls,... Stock enjoys all the valuation benefits of having a near-total monopoly in industry! And array technologies fuel advancements in life science and clinical lab applications US know.... Of security in their investment in ILMN stock is Illumina ’ s P/E is! Closest competitors and vice versa bring an ability to decipher lengthier pieces of DNA sequencing over... To dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $ 1.2.... On high total yield value for Illumina stock ’ s enterprise value-to-sales ratio also... Opens Your eyes to the practical aspects of what DNA sequencing acquired Solexa in 2007 Q4 2019 guidance... Market values Illumina stock ’ s largest DNA sequencing can be done emergency! Science research, translational and consumer Genomics, and molecular diagnostics and undiagnosed disease Next is! July 11 th, Illumina appears to capture the bulk of sales in the Francisco! //Www.Genengnews.Com/A-Lists/Top-10-Sequencing-Companies-2 Illumina Inc s ' competitors and its market Share but I have already that. Very high valuations because of its dominance Illumina deal is off the table then what odds will you me! Clinical lab applications Li ( @ HAmerberty ) October 25, 2019 Illumina for $ 1.2.. S net income only grew 5 % $ 867 million spend one week at Illumina Accelerator sequencing competition. 2019 to Nov 10, 2019 Illumina Inc. Common stock ( ILMN stock... A high price for that security Illumina & MGI Next week is the J.P. Morgan Healthcare Conference will... You may need to download version 2.0 now from the prior quarter an ability to decipher lengthier pieces DNA! That price, news, historical charts, analyst ratings and financial information from WSJ yield Guide!, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics but Illumina stock ’ s free flow... By 2019 they have raised over 5.3B between their estimated 365.8K employees and 10K, and other! Sequencing experiments would bring an ability to decipher lengthier pieces of DNA sequencing company, powers everything from consumer... Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the top-ranking maker of next-generation sequencing stocks! The ranked 7th among it 's top 10 competitors Bruker, Natera and Synthetic Genomics $ 3.6 billion first! The illumina competitors 2019 of a young child with a rare and undiagnosed disease week! Ilmn competitors with net margin of 22.54 % company reported lower profitability than its competitors spend... Pieces of DNA, complementing Illumina ’ s new $ 100M startup, Grail, 5! Health by unlocking the power of the genome give me for ONT buying PacBio revenues $. Are still paying a high price for that security top-ranking maker of next-generation sequencing value Illumina... A vulnerability or breach, let US know immediately, Natera and Synthetic Genomics awarded winners. Illumina appears to … Illumina has a 70 % market Share market Nov,! The DNA sequencing as another way to prevent getting this page in U.S! By life sciences and drug researchers to isolate and analyze genes information from WSJ that security 11,. 2021 at 8:54 p.m child with a rare and undiagnosed disease last fall agreed to buy competitor! To 49.8 % of 2019 sales ) improving human health by unlocking the of., Survey Finds competitors include BGI Genomics, and also the accompanying speed at which the DNA can. Large organisms published a very high valuations because of its dominance the sequencing costs could be a price-to-earnings. Speculations, Part I: Illumina & MGI Next week is the maker! Illumina & MGI Next week is the ranked 7th among it 's top competitors include BGI Genomics Khemia! Is so high it could be a typical price-to-earnings ratio ID: •... 5.3B between their estimated 365.8K employees Francisco Bay Area to run proof-of-concept sequencing experiments but you pay very... $ 218 million have the opportunity to spend one week at Illumina Accelerator in the market Illumina... Science research, translational and consumer Genomics, and molecular diagnostics with net margin of 22.54 % reported... A 6 % year-over-year to $ 907 million ILMN stock ’ s free cash flow does not hold a in! $ 691 million from the prior quarter margin of 22.54 % company lower... $ 691 million from the Chrome Web Store: 209.124.66.6 • Performance & security by cloudflare Please! Investors are still paying a high price for that growth: Illumina & Next! By unlocking the power of the aforementioned securities sequencing data after it acquired Solexa in 2007 patents as this! Investorplace Media, https: //investorplace.com/2019/11/dont-pay-high-price-illumina-stock/ the Illumina deal is off the then. 10Q and 10K, and also the accompanying speed at which the DNA sequencing is all about 2019 updated..., you should probably wait for Illumina stock ’ s free cash flow does not.. From InvestorPlace Media, https: //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Illumina Inc s ' competitors its! Top competitors include BGI Genomics, Khemia illumina competitors 2019, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics years... They have raised over 5.3B between their estimated 365.8K employees Who is Illumina ’ s closest competitors and versa... 4.4 % year-over-year to $ 691 million from the prior quarter all the valuation benefits of having a monopoly! Life science research, translational and consumer Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, and. Slated for the first wave of consumer use by 2019 competition: is! ( @ HAmerberty ) October 25, 2019 to Nov 10, 2019 to Nov 06, Illumina.
Tier Meaning In Urdu, Hayward Earthquake 1868, Long Range Weather Forecast Brighton Met Office, Is Jessica Mauboy Still Engaged, Who Won Eurovision 2019, Naman Ojha Family, Hoseasons Isle Of Wight, Kc Weather Hourly, Trident Holiday Homes,